In terms of financial performance, Cellectis reported revenues exceeding $16 million from research cost reimbursements by collaborators in the third quarter of 2024. The company's latest twelve-month revenue stands at $54.75 million, representing an impressive growth of 351% year-over-year, though InvestingPro analysts anticipate a sales decline in the current year. Operating expenses for the same period were $28.8 million, with a quarter-end cash balance of $264 million, a significant increase from $165 million at the end of 2023.